Cellumed Co

Cellumed Co CROIC

The Cash Return on Invested Capital (CROIC) of Cellumed Co (049180.KQ) as of Oct 28, 2026 is -49.48 %. In the previous year, Cash Return on Invested Capital (CROIC) was -13.61 % — a change of 263.60% (lower).

CROIC

-49.48 %

YoY

263.60%

Last updated:

Cash Return on Invested Capital (CROIC) of Cellumed Co is 2025 -49.48 % . Cash Return on Invested Capital (CROIC) of Cellumed Co was 2024 -13.61 % . It decreases by 263.60% lower compared to the previous year.

The Cellumed Co CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-7.04 KRW
Jan 1, 2019
-28.53 KRW
Jan 1, 2020
-13.77 KRW
Jan 1, 2021
-25.49 KRW
Jan 1, 2022
-23.65 KRW
Jan 1, 2023
-44.17 KRW
Jan 1, 2024
-13.61 KRW
Jan 1, 2025
-49.48 KRW
The Cellumed Co CROIC history
YEARCROICYoY
-49.48 %+263.60%
-13.61 %-69.19%
-44.17 %+86.80%
-23.65 %-7.23%
-25.49 %+85.12%
-13.77 %-51.74%
-28.53 %+305.55%
-7.04 %-44.73%
-12.73 %-24.64%
-16.89 %+60.30%
-10.54 %-32.02%
-15.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cellumed Co Stock analysis

What does Cellumed Co do? Cellumed Co Ltd manufactures and distributes medical devices and biomaterials, including allografts for tissue repair, bone sponges, bone powders, and demineralized bone matrixes (DBMs) for bone regeneration. The company also produces biosimilars like bone morphogenetic protein 2 (BMP2) reagents and medical devices such as spinal fixation systems, joint replacements, and navigation systems. Cellumed sells these products domestically in Seoul and internationally to overseas markets. Cellumed’s primary customers are healthcare providers and medical institutions that require tissue repair solutions, bone regeneration products, and advanced medical devices. The company’s product portfolio targets orthopedic and spinal care segments, with a focus on biomaterials and surgical tools. Its biosimilars, including BMP2 reagents, cater to specialized medical applications requiring bone growth stimulation. The company generates revenue through direct sales of its medical devices and biomaterials to hospitals, clinics, and international distributors. Cellumed’s domestic market in Seoul serves local healthcare facilities, while its overseas sales expand its reach to global medical markets. The firm’s product range supports both routine and complex surgical procedures in orthopedics and spinal care. Cellumed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellumed Co stock

Cash Return on Invested Capital (CROIC) of Cellumed Co is -49.48 % in 2025.

Cash Return on Invested Capital (CROIC) of Cellumed Co changed from -13.61 % to -49.48 %, representing a 263.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Cellumed Co since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Cellumed Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Cellumed Co

All Key Metrics — Cellumed Co